MORE►
Catalyze Dallas Holdings
David Gascoigne, CEO of Almaden Genomics [Photo: Almaden]
Dallas’ Almaden Genomics Launches New Data Management and Informatics Service Business
by David Seeley | Sep 18, 2024
Almaden—which was formerly part of IBM Research before launching as a standalone company in 2022 under Catalyze Dallas ownership—aims to complement its g.nome workflow platform with the new service business. The goal: providing solutions that streamline data analysis and management in drug discovery, diagnostics, biotech research, and more.
by David Seeley |
Jan 30, 2023
Life sciences industry veteran David Gascoigne will lead the new startup, which was launched in October by Catalyze Dallas Holdings.
Almaden's g.nome cloud-native platform offers "an advanced visual drag-and-drop workflow builder" and curated library of toolkits that can speed bioinformatic pipeline building "from what previously has taken months to mere hours," the company says.
MORE►
by Kevin Cummings |
Oct 25, 2022
The Dallas-based venture development firm—which specializes in the commercialization of technology it acquires from Fortune 100 companies—has launched Almaden Genomics, a company with a newly released platform designed to streamline genomic workflows. Formerly part of IBM Research before its acquisition by Catalyze Dallas, Almaden calls its g.nome platform "a revolutionary approach to bioinformatics."
“The possibilities for the healthcare innovation it can power are as vast as they are life-changing," says Mark Kunitomi, Almaden's chief scientific officer.
MORE►
